EUROIMMUN announces option agreement on Zika virus serology
EUROIMMUN and Roche announced early April 2017 that they have entered into an option agreement under which Roche gains access to intellectual property in the field of Zika virus immunodiagnostics assigned to EUROIMMUN. In January 2016, EUROIMMUN became the first company in the world to launch antibody tests that are capable of indicating both an […]
